Abstract
BRCA1/BRCA2 germline mutations substantially increase breast and ovarian cancer risk, yet penetrance is incomplete. We hypothesized that germline epigenetic gene silencing may affect mutant BRCA1/2 penetrance. To test this notion, we determined the methylation status, using methylation-specific quantitative PCR of the promoter in putative modifier genes: BRCA1, BRCA2, ATM, ATR and P53 in Jewish BRCA1/BRCA2 mutation carriers with (n = 41) or without (n = 48) breast cancer, in sporadic breast cancer (n = 52), and healthy controls (n = 89). Promoter hypermethylation was detected only in the BRCA1 promotor in 5.6–7.3% in each of the four subsets of participants, regardless of health and BRCA1/2 status.Germline promoter hypermethylation in the BRCA1 gene can be detected in about 5% of the female Israeli Jewish population, regardless of the BRCA1/2 status. The significance of this observation is yet to be determined.
Similar content being viewed by others
References
Wacholder S, Struewing JP, Hartge P, Greene MH, Tucker MA (2004) Breast cancer risks for BRCA1/2 carriers. Science 306:2187–2191
Robles-Diaz L, Goldfrank JD, Kauff ND, Robson M, Offit K (2004) Hereditary ovarian cancer in Ashkenazi Jews. Fam Cancer 3:259–264
Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1 mutation carriers Breast Cancer Linkage Consortium. Am J Hum Genet 56:265–271
Narod SA, Goldgar D, Cannon-Albright L, Weber BL, Moslehi R, Ives E, Lenoir G, Lynch H (1995) Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 64:394–398
Ford D, Easton DF, Stratton M, Narod S et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689
Wylie B, Melissa AA (2002) Genetic risk in context: calculating the penetrance of BRCA1 and BRCA2 mutations. J Natl Cancer Inst 94:1185–1187
Begg CB (2002) On the use of familial aggregation in population-based case probands for calculating penentrance. J Natl Cancer Inst 94:1221–1226
Kenneth O (2006) BRCA mutation frequency and penetrance: new data, old debate. J Natl Cancer Inst 98:1675–1677
Narod SA (2006) Modifiers of risk of hereditary breast cancer. Oncogene 25:832–5836
Levy-Lahad E, Friedman E (2007) Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 96:11–15
Antoniou AC, Sinilnikova OM, Simard J, Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) (2007) RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 81:1186–1200
Baylin SB, Chen WY (2005) Aberrant gene silencing in tumor progression: implications for control of cancer. Cold Spring Harb Symp Quant Biol 70:427–433
Bastian PJ, Yegnasubramanian S, Palapattu G, Rogers C, Lin X, Marzo AD, Nelson W (2004) Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol 46:698–708
Feinberg AP (2001) Cancer epigenetics takes center stage. Proc Natl Acad Sci U S A 98:392–394
Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG (2001) Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10:687–692
Cross SH, Bird AP (1995) CpG islands and genes. Curr Opin Genet Dev 5:309–314
Attwood JT, Yung RL, Richardson BC (2002) DNA methylation and the regulation of gene transcription. Cell Mol Life Sci 59:241–257
Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428
Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042–2054
Bird A, Taggart M, Frommer M, Miller OJ, Macleod D (1985) A fraction of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA. Cell 40:91–99
Dobrovic A, Simpfendorfer D (1997) Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 57:3347–3350
Suter CM, Martin DI, Ward RL (2004) Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet 36:497–501
Chan TL, Yuen ST, Kong CK, Chan YW, Chan AS, Ng WF, Tsui WY, Lo MW, Tam WY, Li WY, Leung SY (2006) Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet 38:1178–1183
Weisenberger DJ, Siegmund DK, Campan M et al (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38:787–793
Chan KY, Ozçelik H, Cheung AN, Ngan HY, Khoo US (2002) Epigenetic Factors Controlling the BRCA1 and BRCA2 Genes in Sporadic Ovarian Cancer. Cancer Res 62:4151–4156
Kang JH, Kim SJ, Noh D, Park IA, Choe KJ, Yoo OJ, Kang H (2001) Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma. Lab Invest 81:573–579
Treilleux I, Chapot B, Goddard S, Pisani P, Ange`le S, Hall J (2007) The molecular causes of low ATM protein expression in breast carcinoma; promoter methylation and levels of the catalytic subunit of DNA-dependent protein kinase. Histopathology 51:63–69
Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, Olopade OI (2005) BRCA1 Promoter Methylation in Sporadic Breast Cancer Is Associated with Reduced BRCA1 Copy Number and Chromosome 17 Aneusomy. Cancer Res 65:10692–10699
Snell C, Krypuy M, Wong EM, kConFab investigators, Loughrey MB, Dobrovic A (2008) BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res 10:R12
Chen Y, Amanda E, McLennan TJ, Fridlyand J, Crawford B, Costello JF, John LZ (2006) Lack of germ-line promoter methylation in BRCA1-negative families with familial breast cancer. Genet Test 10:281–284
Acknowledgements
This study was done in part as fulfillment for the degree of Master of Sciences by Tair Knntorovich at the Department of life science, Bar Ilan University. This study was in part funded by a grant from the Israel cancer association to Eitan Friedman.
Author information
Authors and Affiliations
Corresponding author
Additional information
Tair Kontorovich and Yoram Cohen contributed equally to this work.
Rights and permissions
About this article
Cite this article
Kontorovich, T., Cohen, Y., Nir, U. et al. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. Breast Cancer Res Treat 116, 195–200 (2009). https://doi.org/10.1007/s10549-008-0121-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-008-0121-3